Caution at psychiatry's psychedelic frontier.

@article{Burke2021CautionAP,
  title={Caution at psychiatry's psychedelic frontier.},
  author={Matthew J. Burke and Daniel M. Blumberger},
  journal={Nature medicine},
  year={2021}
}
3 Citations
Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results.
TLDR
Many people with FND seek alternative means of symptom management outside usual medical care, including legal and illicit psychoactive substances, and further research exploring novel treatment options in FND may be warranted.
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.
RATIONALE Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However,
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders
TLDR
Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support, and both agents were well tolerated in supervised trials.

References

SHOWING 1-10 OF 10 REFERENCES
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
TLDR
The data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities.
Trial of Psilocybin versus Escitalopram for Depression.
TLDR
This phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients.
Tripping on nothing: placebo psychedelics and contextual factors
TLDR
Understanding how context and expectations promote psychedelic-like effects, even without the drug, will help researchers to isolate drug effects and clinicians to maximise their therapeutic potential.
Placebo and Nocebo Effects.
Placebo and Nocebo Effects Placebo and nocebo effects (effects of patients’ positive and negative expectations) are powerful and pervasive in clinical practice. Neurobiologic mechanisms, informatio...
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
TLDR
MDMA-assisted psychotherapy was efficacious and well tolerated in a large sample of adults with PTSD and supported expansion into phase 3 trials and led to FDA granting Breakthrough Therapy designation for this promising treatment.
Challenges of differential placebo effects in contemporary medicine: The example of brain stimulation
TLDR
This Neurology Grand Rounds uses transcranial magnetic stimulation as a model to explore the principles and implications of differential placebo effects and analyzes fundamental questions of measuring efficacy in contemporary medicine.
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
TLDR
The latest version of the CONSORT statement, CONSORT 2010, is described, which updates the reporting guideline based on new methodological evidence and accumulating experience.
Brain Mechanisms of the Placebo Effect: An Affective Appraisal Account.
TLDR
It is suggested that placebos affect behavior and physiology by changing how a person evaluates their future well-being and the personal significance of their symptoms.
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
TLDR
This study provides the first evidence for rapid reduction in symptom severity following ketamine infusion in patients with chronic PTSD, and may lead to novel approaches to the pharmacologic treatment of patients with this disabling condition.